₩4,285.00 ($3.18)

-70.00 (-1.61%)

Weekly Expected Move ±2.3%

₩4085 ₩4185 ₩4285 ₩4385 ₩4485

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 60 · ₩296.5B mcap · 28M float · 0.328% daily turnover

Revenue

$969.0B +9.2% ▲

5Y CAGR: +4.4%

Gross Profit

$472.9B +8.7% ▲

5Y CAGR: +9.0%

Operating Income

$163.7B +11.7% ▲

5Y CAGR: +34.4%

Net Income

$58.5B -6.6% ▼

5Y CAGR: +45.2%

EPS (Diluted)

$840.93 -3.8% ▼

5Y CAGR: +46.9%

EBITDA

$207.3B -10.4% ▼

5Y CAGR: +17.5%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$788.9B	$864.5B	$928.1B	$887.7B	$969.0B
YoY Growth	+0.9%	+9.6%	+7.3%	-4.3%	+9.2%
Cost of Revenue	$444.8B	$464.6B	$481.9B	$452.5B	$496.6B
Gross Profit	$344.2B	$400.0B	$446.2B	$435.2B	$472.9B
Gross Margin	43.6%	46.3%	48.1%	49.0%	48.8%
R&D Expenses	$17.8B	$33.1B	$33.7B	$39.1B	$0
SG&A Expenses	$129.6B	$137.0B	$150.6B	$146.1B	$0
Operating Expenses	$275.4B	$273.8B	$301.3B	$288.7B	$309.3B
Operating Income	$62.1B	$103.3B	$144.9B	$146.5B	$163.7B
Operating Margin	7.9%	11.9%	15.6%	16.5%	16.9%
Interest Expense	$21.5B	$25.3B	$32.5B	$32.2B	$19.9B
Income Before Tax	$32.5B	$71.0B	$53.4B	$158.1B	$144.3B
Tax Expense	$28.1B	$24.5B	$22.4B	$35.4B	$28.8B
Net Income	-$2.8B	$22.2B	$19.0B	$62.6B	$58.5B
Net Margin	-0.4%	2.6%	2.1%	7.1%	6.0%
EPS (Diluted)	$-39.32	$306.49	$265.00	$874.26	$840.93
EBITDA	$96.3B	$142.8B	$128.5B	$231.4B	$207.3B
Shares Outstanding	71M	72M	70M	72M	70M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$226.5B	$223.5B	$239.5B	$228.4B	$244.1B	$257.0B	$243.2B	$266.5B
Cost of Revenue	$107.6B	$116.6B	$121.9B	$108.0B	$121.5B	$136.0B	$117.4B	$132.5B
Gross Profit	$118.9B	$106.9B	$117.7B	$120.4B	$122.6B	$121.5B	$125.8B	$134.0B
Gross Margin	52.5%	47.9%	49.1%	52.7%	50.2%	47.3%	51.7%	50.3%
R&D Expenses	$9.7B	$11.8B	$0	$13.2B	$7.9B	$16.7B	$10.6B	$12.4B
SG&A Expenses	$57.7B	$39.6B	$75.9B	$79.3B	$40.6B	$35.8B	$39.1B	$43.1B
Operating Expenses	$71.5B	$76.5B	$75.9B	$79.3B	$75.4B	$92.9B	$74.3B	$80.2B
Operating Income	$47.3B	$30.7B	$41.8B	$41.0B	$47.2B	$38.0B	$51.5B	$53.8B
Operating Margin	20.9%	13.7%	17.4%	18.0%	19.3%	14.8%	21.2%	20.2%
Interest Expense	$8.3B	$7.9B	$5.6B	$9.8B	$8.4B	-$4.0B	$7.9B	$7.1B
Income Before Tax	$2.8B	$37.6B	$38.2B	$29.6B	$39.5B	$37.0B	$51.6B	$49.8B
Tax Expense	-$19M	$11.5B	$8.7B	$19.5B	-$961M	$1.5B	$11.8B	$8.8B
Net Income	$2.8B	$7.4B	$10.1B	$4.0B	$21.6B	$22.8B	$20.7B	$19.4B
Net Margin	1.2%	3.3%	4.2%	1.8%	8.9%	8.9%	8.5%	7.3%
EPS (Diluted)	$181.00	$105.09	$144.00	$57.42	$310.00	$328.81	$298.70	$281.03
EBITDA	$59.4B	$54.7B	$54.2B	$131.2B	$57.8B	-$35.8B	$61.7B	$65.9B
Shares Outstanding	74M	71M	70M	70M	70M	70M	69M	69M

096760.KS KSC